{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T23:16:24Z","timestamp":1778800584898,"version":"3.51.4"},"reference-count":50,"publisher":"Informa UK Limited","issue":"3","license":[{"start":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T00:00:00Z","timestamp":1708473600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Immunological Medicine"],"published-print":{"date-parts":[[2024,7,2]]},"DOI":"10.1080\/25785826.2024.2311763","type":"journal-article","created":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T08:11:40Z","timestamp":1708503100000},"page":"130-141","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Safety risks of interstitial lung disease upon real-world usage of Janus kinase inhibitors and biologics for patients with autoimmune diseases: epidemiological study using nationwide electronic medical record database in Japan"],"prefix":"10.1080","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-7093-0638","authenticated-orcid":false,"given":"Mihoko","family":"Yabuuchi","sequence":"first","affiliation":[{"name":"Department of Epidemiology and Environmental Health, Juntendo University Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan"},{"name":"Medical Writing, Portfolio and Project Management, Pfizer R&amp;D Japan G.K., Shibuya-ku, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3537-5657","authenticated-orcid":false,"given":"Kazuhito","family":"Yokoyama","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Environmental Health, Juntendo University Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan"},{"name":"Department of Epidemiology and Social Medicine, International University of Health and Welfare Graduate School of Public Health, Minato-ku, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2024,2,21]]},"reference":[{"key":"e_1_3_6_2_1","unstructured":"Mitsubishi Tanabe Pharma Corporation. Japanese interview form of infliximab (REMICADE for I.V. infusion 100); 2022 [cited 2023 Jul 6]. Available from: https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/GeneralList\/2399402"},{"issue":"3","key":"e_1_3_6_3_1","first-page":"393","article-title":"Anti-cytokine therapy in collagen disease and rheumatology \u2013update\u2013: anti-cytokine therapy in allergy and autoimmunity","volume":"108","author":"Tanaka Y.","year":"2019","unstructured":"Tanaka Y. Anti-cytokine therapy in collagen disease and rheumatology \u2013update\u2013: anti-cytokine therapy in allergy and autoimmunity. J Japan Intern Med. 2019;108(3):393\u2013400.","journal-title":"J Japan Intern Med"},{"key":"e_1_3_6_4_1","unstructured":"Pfizer. Japanese interview form of tofacitinib (XELJANZ Tablets 5\u2009mg); 2023 [cited 2023 Jul 6]. Available from: https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/GeneralList\/3999034"},{"key":"e_1_3_6_5_1","unstructured":"Pfizer. Japanese risk management plan of tofacitinib (XEJJANZ Tablets 5\u2009mg); 2023 [cited 2023 Jul 6]. Available from: https:\/\/www.pmda.go.jp\/safety\/info-services\/drugs\/items-information\/rmp\/0001.html"},{"key":"e_1_3_6_6_1","unstructured":"Eli Lilly and Company. Japanese risk management plan of baricitinib (Olminant tablets 4\u2009mg\/2\u2009mg); 2023 [cited 2023 Jul 6]. Available from: https:\/\/www.pmda.go.jp\/safety\/info-services\/drugs\/items-information\/rmp\/0001.html"},{"key":"e_1_3_6_7_1","unstructured":"Astellas. Japanese risk management plan of peficitinib (Smyraf Tablets 50\u2009mg\/100\u2009mg); 2022 [cited 2023 Jul 6]. Available from: https:\/\/www.pmda.go.jp\/safety\/info-services\/drugs\/items-information\/rmp\/0001.html"},{"key":"e_1_3_6_8_1","unstructured":"AbbVie. Japanese risk management plan of upadacitinib (RINVOC Tablets 45\u2009mg\/30\u2009mg\/15\u2009mg\/7.5\u2009mg); 2023 [cited 2023 Jul 6]. Available from: https:\/\/www.pmda.go.jp\/safety\/info-services\/drugs\/items-information\/rmp\/0001.html"},{"key":"e_1_3_6_9_1","unstructured":"GILEAD. Japanese risk management plan of filgotinib (Jyseleca Tablets 200\u2009mg\/100\u2009mg); 2023 [cited 2023 Jul 6]. Available from: https:\/\/www.pmda.go.jp\/safety\/info-services\/drugs\/items-information\/rmp\/0001.html"},{"key":"e_1_3_6_10_1","unstructured":"Ministry of Health Labour and Welfare. Manual for serious adverse drug reactions: interstitial pneumonia (pneumonia alveolitis and pulmonary fibrosis); 1996 [cited 2023 Jul 6]. Available from: https:\/\/www.info.pmda.go.jp\/juutoku\/file\/jfm1909009.pdf"},{"key":"e_1_3_6_11_1","unstructured":"Japanese Respiratory Society. Abbreviated version: diagnosis and treatment guideline of drug-induced lung injury; Bunkyo-ku 2013."},{"key":"e_1_3_6_12_1","unstructured":"Japanese Respiratory Society. Biologics and respiratory diseases: clinical guidelines; Bunkyo-ku 2014."},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.3109\/03009741003604542"},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.27405"},{"key":"e_1_3_6_15_1","unstructured":"Japan College of Rheumatology. Guidelines for TNF inhibitors treatment for rheumatoid arthritis; 2023 [cited 2023 Jul 6]. Available from: https:\/\/www.ryumachi-jp.com\/pdf\/guideline_tnf_230323.pdf"},{"key":"e_1_3_6_16_1","unstructured":"Mitsubishi Tanabe Pharma Corporation. Japanese package inserts of infliximab (REMICADE for I.V. infusion 100); 2022 [cited 2023 Jul 6]. Available from: https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/400315_2399402F1026_1_44"},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-015-0835-7"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu165"},{"key":"e_1_3_6_19_1","unstructured":"Pfizer. Japanese package inserts of tofacitinib (XELJANZ Tablets 5\u2009mg); 2022 [cited 2023 Jul 6]. Available from: https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/GeneralList\/3999034"},{"key":"e_1_3_6_20_1","unstructured":"Eli Lilly and Company. Japanese package inserts of baricitinib (Oluminant tablets 4\u2009mg\/2\u2009mg); 2022 [cited 2023 Jul 6]. Available from: https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/GeneralList\/3999043"},{"key":"e_1_3_6_21_1","unstructured":"Astellas. Japanese package inserts of peficitinib (Smyraf Tablets 50\u2009mg\/100\u2009mg); 2021 [cited 2023 Jul 6]. Available from: https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/GeneralList\/3999046"},{"key":"e_1_3_6_22_1","unstructured":"AbbVie. Japanese package inserts of upadacitinib (RINVOC Tablets 45\u2009mg\/30\u2009mg\/15\u2009mg\/7.5\u2009mg); 2023 [cited 2023 Jul 6]. Available from: https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/GeneralList\/3999048"},{"key":"e_1_3_6_23_1","unstructured":"GILEAD. Japanese package inserts of filgotinib (Jyseleca Tablets 200\u2009mg\/100\u2009mg); 2022 [cited 2023 Jul 6]. Available from: https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/GeneralList\/3999053"},{"key":"e_1_3_6_24_1","unstructured":"Japan College of Rheumatology. Japanese proper use guide for all patients post-marketing study of tofacitinib; 2023 [cited 2023 Jul 6]. Available from: https:\/\/www.ryumachi-jp.com\/pdf\/guideline_tofacitinib_230323.pdf"},{"key":"e_1_3_6_25_1","unstructured":"Japan College of Rheumatology. Japanese proper use guide for all patients post-marketing study of baricitinib; 2022 [cited 2023 Jul 6]. Available from: https:\/\/www.ryumachi-jp.com\/publish\/guide\/guideline_barishichinibu\/"},{"key":"e_1_3_6_26_1","unstructured":"Japan College of Rheumatology. Japanese proper use guide for all patients post-marketing study of peficitinib; 2022 [cited 2023 Jul 6]. Available from: https:\/\/www.ryumachi-jp.com\/publish\/guide\/guideline_peficitinib\/"},{"key":"e_1_3_6_27_1","unstructured":"Japan College of Rheumatology. Japanese proper use guide for all patients post-marketing study of \u00adupadacitinib; 2022 [cited 2023 Jul 6]. Available from: https:\/\/www.ryumachi-jp.com\/publish\/guide\/guideline_upadacitinib\/"},{"key":"e_1_3_6_28_1","unstructured":"Japan College of Rheumatology. Japanese proper use guide for all patients post-marketing study of filgotinib; 2022 [cited 2023 Jul 6]. Available from: https:\/\/www.ryumachi-jp.com\/publish\/guide\/guideline_filgotinib\/"},{"key":"e_1_3_6_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa117"},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key287"},{"issue":"10","key":"e_1_3_6_31_1","first-page":"431","article-title":"AB0431 post-marketing surveillance tofacitinib in Japanese patients with rheumatoid arthritis: an interim report of safety data (abstract)","volume":"69","author":"Mimori T","year":"2017","unstructured":"Mimori T, Harigai M, Atsumi T, et\u00a0al. AB0431 post-marketing surveillance tofacitinib in Japanese patients with rheumatoid arthritis: an interim report of safety data (abstract). Arthritis Rheumatol. 2017;69(Suppl. 10):431.","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"e_1_3_6_32_1","first-page":"1408","article-title":"AB0495 post-marketing surveillance of tofacitinib in Japanese patients with rheumatoid arthritis: an interim report of safety data (abstract)","volume":"77","author":"Tamura N","year":"2018","unstructured":"Tamura N, Kuwana M, Atsumi T, et\u00a0al. AB0495 post-marketing surveillance of tofacitinib in Japanese patients with rheumatoid arthritis: an interim report of safety data (abstract). Ann Rheum Dis. 2018;77(Suppl. 2):1408.","journal-title":"Ann Rheum Dis"},{"key":"e_1_3_6_33_1","doi-asserted-by":"publisher","DOI":"10.1177\/106002808702101114"},{"key":"e_1_3_6_34_1","unstructured":"Japan College of Rheumatology. Guideline for the management of rheumatoid arthritis 2020; Chiyoda-ku 2021."},{"key":"e_1_3_6_35_1","unstructured":"Ministry of Health Labour and Welfare (Hisamatsu Research Group). Ulcerative colitis and Crohn\u2019s disease diagnostic criteria and treatment guideline (2022 revised version) 31 Mar 2023: report of the fiscal year 2022 joint research project; 2023 [cited 2023 Jul 6]. Available from: http:\/\/www.ibdjapan.org\/pdf\/doc15.pdf"},{"key":"e_1_3_6_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2010.11.028"},{"key":"e_1_3_6_37_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.120626"},{"key":"e_1_3_6_38_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0039-1683995"},{"key":"e_1_3_6_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2014.149"},{"key":"e_1_3_6_40_1","doi-asserted-by":"publisher","DOI":"10.2745\/dds.35.376"},{"key":"e_1_3_6_41_1","unstructured":"Furukawa H Tohma S. Association of HLA with interstitial lung lesions frequently associated with elderly rheumatoid arthritis patients; 2023 [cited 2023 Jul 6]. Available from: https:\/\/www.ms-ins.com\/welfare\/document\/list\/pdf\/2012\/3_1_18.pdf"},{"issue":"1","key":"e_1_3_6_42_1","first-page":"1","article-title":"Genetics of interstitial lung disease: vol de nuit (night flight)","volume":"9","author":"Furukawa H","year":"2015","unstructured":"Furukawa H, Oka S, Shimada K, et\u00a0al. Genetics of interstitial lung disease: vol de nuit (night flight). Clin Med Insights Circ Respir Pulm Med. 2015;9(Suppl. 1):1\u20137.","journal-title":"Clin Med Insights Circ Respir Pulm Med"},{"key":"e_1_3_6_43_1","unstructured":"Health Clinic Education Information Evaluation Institute (HCEI); 2023 [cited 2023 Jul 6]. Available from: https:\/\/www.hcei.or.jp\/"},{"key":"e_1_3_6_44_1","unstructured":"RWD Ltd. RWD website; 2023 [cited 2023 Jul 6]. Available from: https:\/\/rwdata.co.jp\/company\/"},{"key":"e_1_3_6_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.2216"},{"key":"e_1_3_6_46_1","doi-asserted-by":"publisher","DOI":"10.37737\/ace.23002"},{"key":"e_1_3_6_47_1","unstructured":"Personal Information Protection Commission JAPAN. Guideline on the Act on the Protection of Personal Information; 2016 [cited 2023 Jul 6]. Available from: https:\/\/www.ppc.go.jp\/personalinfo\/legal\/guidelines_tsusoku\/"},{"key":"e_1_3_6_48_1","unstructured":"Health Clinic Education Information Evaluation Institute (HCEI). Youshiki-4 \u201cTerms of use for anonymously processed medical and health information\u201d; 2023 [cited 2023 Jul 6]. Available from: https:\/\/www.hcei.or.jp\/page\/application-forms"},{"key":"e_1_3_6_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.13190"},{"key":"e_1_3_6_50_1","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S293698"},{"key":"e_1_3_6_51_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00659-w"}],"container-title":["Immunological Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/25785826.2024.2311763","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T21:20:42Z","timestamp":1727212842000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/25785826.2024.2311763"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,21]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,7,2]]}},"alternative-id":["10.1080\/25785826.2024.2311763"],"URL":"https:\/\/doi.org\/10.1080\/25785826.2024.2311763","relation":{},"ISSN":["2578-5826"],"issn-type":[{"value":"2578-5826","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,21]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=timm20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=timm20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-10-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}